Thyroid pharma
-
Canadian LT3 brands: TEVA vs. Cytomel bioequivalence, fasted vs. fed
Did you know that Canadian TEVA LT3 has a much faster-release effect than Canadian Cytomel LT3 in the fasted state? They are not bioequivalent in all ways, despite Health Canada approval following a bioequivalence study. In addition, both Canadian brands have a “slower-release” effect when dosed on a full stomach and a lower maximum peak.…
-
RLC Labs issues Nature-Throid and WP-thyroid recall for subpotency
Oh my. Now another American desiccated thyroid (NDT) brand recall? Earlier this year, Acella’s NP thyroid was found to be superpotent (over 110% on the T3 content), and they issued a voluntary recall. Now, as of August 25, 2020, Nature-Throid and/or WP-Thyroid are sub-potent, so their manufacturer RLC Labs is issuing a voluntary recall. QUOTE:…
-
Acella NP Thyroid recall: maternal risk inflated
Acella, the makers of NP Thyroid, issued a voluntary recall notice on May 22, 2020. This is part 2 of a two-part series reviewing the drug recall notice’s statements and the science behind them. [Part 1: Acella NP Thyroid recall: Ethical yet low-risk] We should applaud Acella for being so conscientious about the exact amounts…
-
Acella NP Thyroid recall: Ethical yet low-risk
Acella, the makers of NP Thyroid, issued a voluntary recall notice on May 22, 2020. This is part 1 of a two-part series reviewing the drug recall notice’s statements and the science behind them. In this post, I put this recall in the context of pharmaceutical guidelines and manufacturing challenges. I also portray the variable…
-
Thyroid patient blaming and shaming, part 3: Advocacy and Science
In this Part 3, I continue my rebuttal of a research article that blames thyroid patients for causing harm to themselves by making requests of doctors for tests and therapies. In this post, I explain the good signs that thyroid patients’ self-advocacy is sometimes effective and is making a difference.